ClinicalTrials.gg
CompletedNCT05930119Updated Sep 6, 2023

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

A Phase 1 interventional study of HMPL-453 and Rabeprazole in Intrahepatic Cholangiocarcinoma, sponsored by Hutchmed. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by Hutchmed · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies in Cholangiocarcinoma with a site in China — 114 open to participants now, 125 under way, 12 of them phase 3. Cholangiocarcinoma · China.

Enrollment
165th of 191
24 · median 51
Started
2023
with 24 others
Phase 1
19 of 230
10 open now
Registered
127th of 230
by date

Among the 230 studies in Cholangiocarcinoma with a site in China, this one is the 165th largest by enrollment of the 191 interventional ones that give a count, is one of 25 that started in 2023, is one of 19 in phase 1, and was the 127th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

114 of the 230 studies in Cholangiocarcinoma with a site in China are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Cholangiocarcinoma with a site in China, or all of them as a file.
02

Study summary

A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers

03

Conditions studied

  • Intrahepatic Cholangiocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have fully understood the study and voluntarily signed the form;
  2. The volunteer is male or female between the ages of 18 and 55 years old (inclusive) at the time of informed consent.
  3. The volunteer has a (BMI)>18 and ≤29.9 kg/m2at screening. Male need≥50 kg,famele need≥45 kg.
  4. Female with fertility agree to adopt efficient measures within 6 months after signing ICF until the end of the last HMPL-453 dosing, and agree not to donate eggs (or oocytes) for reproductive purposes during this period. Acceptable and efficient contraceptive methods include complete abstinence, bilateral tubal ligation, oral or injection contraceptives, intrauterine devices, or partner vas deferens ligation. All hormonal contraception measures must be combined with barrier measures such as the use of condoms by spouses. More information can be found in Attachment 12.3 [Definition of Women with Fertility () and Acceptable and Unacceptable Contraceptive Methods].
  5. Male patients is willing to take contraception measures (during the study and for 3 months after the end of study treatment). Male patients should avoid donating or freezing sperm during this period.
  6. The volunteer is willing and able to comply with all aspects of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. The volunteer has a known history of any gastrointestinal surgery or any condition possibly affecting drug absorption (eg, cholecystectomy, gastrectomy, achlorhydria, peptic ulcer disease, or history of stomach or intestinal surgery or resection).
  2. The volunteer had a illness within 8 weeks or a clinically significant infection within 4 weeks prior to the first dose.
  3. The volunteer has evidence of a clinically significant deviation from normal in the physical examination, vital signs, or clinical laboratory determinations at screening or at Day -1 check-in (baseline).
  4. The volunteer has systolic blood pressure >140 mmHg diastolic blood pressure >90mmHg.
  5. Currently keratopathy confirmed by ophthalmological examination, including but not limited to bullae keratopathy, zonal corneal degenerations, corneal abrasion, corneal ulcer, and sclerokeratitis.
  6. Current or prior history of retinal detachment.
  7. The volunteer has a clinically significant abnormality, including a marked baseline prolongation of /QTc interval (eg, repeated demonstration of a QTcF interval >480msec), or hasa family history of prolonged QTc syndrome or sudden death.
  8. Volunteers who smoke more than 10 cigarettes per day within the first 3 months of screening and are unable to completely quit smoking during the study period.
  9. Volunteers who frequently drink alcohol within the first 6 months before screening, drink more than 14 units of alcohol per week。
  10. The volunteer has a history of drug misuse within 6 months prior to screening (including those who have tested positive for morphine, methylenedioxymethamphetamine, methamphetamine, tetrahydrocannabinol acid, ketamine, cocaine, or a positive urine drug test at screening or at check-in).
  11. The volunteer has been diagnosed with acquired immune deficiency syndrome or has performed tests that are positive for (HIV), virus (HBV), or virus (HCV).
  12. The volunteer has a clinically significant X-ray,
  13. The volunteer has participated in a clinical trial of other study drug before screening, and the time since the last use of other study drug is less than 5 times the half-life or 4 weeks, whichever is longer, or the volunteer is currently enrolled in another clinical trial.
  14. The volunteer has used strong inducer or strong inhibitor, any over-the-counter (OTC) medications or prescription drugs (medications that can lower gastric acid in particular) within 2 weeks prior to the first dose.
  15. The volunteer has consumed alcohol, grapefruit, lime, and caffeine within 72 hours prior to the first dose.
  16. Taking drugs or dietary supplements (such as calcium, phosphorus, vitamin D, parathyroid hormone, etc.) that may cause blood phosphorus and/or blood calcium to rise within 2 weeks prior to the start of the study treatment.

18.Needle sickness, blood sickness or difficulty in collecting venous blood. 19.The volunteer is allergic to any of the study drugs (or its ) to be given in this study.

20.A female participant is pregnant, lactating, or breastfeeding. 21.Any other medical condition judged by the investigator would make the patients unsuitable to participate in this study.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    fast overnight

    Subjects in treatment A will administered HMPL-453 at fast overnight condition.

    Drug: HMPL-453

  • Experimental
    high-fat meal

    Subjects in treatment B will administered HMPL-453 at high-fat meal condition.

    Drug: HMPL-453

  • Experimental
    low-fat meal

    Subjects in treatment C will administered HMPL-453 at low-fat meal condition.

    Drug: HMPL-453

  • Experimental
    rabeprazole

    Subjects in treatment D will administered rabeprazole combined with HMPL-453 at low-fat meal condition hour prior to receiving a standardized low-fat meal.

    Drug: HMPL-453 · Drug: Rabeprazole

Interventions

  • 300 mg HMPL-453

  • 20 mg of rabeprazole will be administered by mouth once daily.

06

What researchers measure

Primary outcomes

  1. PK parameter for HMPL-453: AUC0-t

    Area under the concentration time curve from time 0 to the last measurable concentration

    Time frame: Day 1 to Day 33

  2. PK parameter for HMPL-453: AUC0-inf

    Area under the concentration time curve from time 0 extrapolated to infinity

    Time frame: Day 1 to Day 33

  3. PK parameter for HMPL-453: Cmax

    Maximum observed plasma concentration

    Time frame: Day 1 to Day 33

Secondary outcomes

  1. Assessment of safety procedures findings

    Any untoward medical occurrence associated with the study drug

    Time frame: Day 1 to Day 33

  2. PK parameter for HMPL-453: tmax,t1/2

    Time to reach the maximum observed plasma concentration, elimination half-life

    Time frame: Day 1 to Day 33

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, Shanghai 200031, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Aug 2023, 5 months.

Of 44 industry-sponsored phase 1 interventional studies under Cholangiocarcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 60. This study's 5 months is below that.

Counting every sponsor, half of 67 studies reached it within 46 months; a quarter within 30 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
Jul 5, 2023
StartActual
Mar 17, 2023
Primary completionActual
Aug 28, 2023
CompletionActual
Aug 28, 2023
Last update
Sep 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05930119
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Jul 5, 2023
Start date
Mar 17, 2023
Primary completion
Aug 28, 2023
Completion
Aug 28, 2023
Last update
Sep 6, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fanregratinib

Start the discussion